amino[5-(2-chlorophenyl)-3-phenyl-2-pyrazolin-1-yl]methane-1-thione | 1146963-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: amino[5-(2-chlorophenyl)-3-phenyl-2-pyrazolin-1-yl]methane-1-thione
• 英文别名: 3-(2-Chlorophenyl)-5-phenyl-3,4-dihydropyrazole-2-carbothioamide
• CAS: 1146963-14-5
• 化学式: C₁₆H₁₄ClN₃S
• 分子量: 315.826
• InChiKey: UKUZMFDTYIIYMM-UHFFFAOYSA-N

物化性质

• 熔点：
  210 °C(Solvent: Chloroform)
• 沸点：
  460.6±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二氯喹喔啉 、 amino[5-(2-chlorophenyl)-3-phenyl-2-pyrazolin-1-yl]methane-1-thione 以 乙醇 为溶剂， 反应 8.0h， 以34%的产率得到2-[5-(2-chlorophenyl)-3-phenyl-2-pyrazolin-1-yl]-1,3-thiazolino[5,4-b]quinoxaline
  参考文献：
  名称：

  新的2-（5-取代的-3-苯基-2-吡唑啉基）-1,3-噻唑啉代[5,4- b ]喹喔啉衍生物的合成及其抗厌氧活性的评价

  摘要：

  在努力开发有效的antiamoebic剂，我们已经合成的查耳酮（1 - 8），2-氨基-5-取代的- （3-苯基（2-吡唑啉基））甲烷-1-硫酮衍生物（1A - 8A）和2-（ 5-取代的-3-苯基-2-吡唑啉基）-1,3-噻唑啉代[5,4- b ]喹喔啉衍生物（1b – 8b）并评估了它们对溶血性大肠杆菌HM1：IMSS菌株的体外抗氧活性。所有化合物的特征在于电子，IR，11 H NMR和质谱数据。观察到，通过改变查耳酮对吡唑啉和进而对喹喔啉的结构，抗厌氧活性增强。在人肾上皮细胞系上进行MTT测定以检查化合物的细胞毒性，并将结果与​​甲硝唑进行比较。与甲硝唑相比，化合物6b具有更好的抗氧活性和更低的毒性。

  DOI：

  10.1016/j.ejmech.2008.02.002
• 作为产物：
  描述：

  苯乙酮 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 32.0h， 生成 amino[5-(2-chlorophenyl)-3-phenyl-2-pyrazolin-1-yl]methane-1-thione
  参考文献：
  名称：

  Structure-guided discovery of 1,3,5-triazine–pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate

  摘要：

  Impressed by the exceptional antibacterial activity exhibited by our earlier designed molecules originating from 1,3,5-triazine, the present study was undertaken to synthesize a novel series of 1,3,5-triazine-pyrazole conjugates to bring diversity around the core skeleton. The target analogues showed potent antibacterial activity against tested Gram-positive and Gram-negative microorganisms. The toxicity and metabolic site prediction studies were also held out to set an effective lead candidate for the future antibacterial drug discovery initiatives. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.103

文献信息

• Synthesis of new 2-(5-substituted-3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]quinoxaline derivatives and evaluation of their antiamoebic activity
  作者：Asha Budakoti、Abdul Roouf Bhat、Amir Azam

  DOI：10.1016/j.ejmech.2008.02.002

  日期：2009.3

  linyl))methane-1-thione derivatives (1a–8a) and 2-(5-substituted-3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]quinoxaline derivatives (1b–8b) and evaluated for their in vitro antiamoebic activity against HM1:IMSS strain of E. histolytica. All the compounds were characterized by electronic, IR, 1H NMR and mass spectroscopic data. It was observed that the antiamoebic activity enhances on modifying the

  在努力开发有效的antiamoebic剂，我们已经合成的查耳酮（1 - 8），2-氨基-5-取代的- （3-苯基（2-吡唑啉基））甲烷-1-硫酮衍生物（1A - 8A）和2-（ 5-取代的-3-苯基-2-吡唑啉基）-1,3-噻唑啉代[5,4- b ]喹喔啉衍生物（1b – 8b）并评估了它们对溶血性大肠杆菌HM1：IMSS菌株的体外抗氧活性。所有化合物的特征在于电子，IR，11 H NMR和质谱数据。观察到，通过改变查耳酮对吡唑啉和进而对喹喔啉的结构，抗厌氧活性增强。在人肾上皮细胞系上进行MTT测定以检查化合物的细胞毒性，并将结果与​​甲硝唑进行比较。与甲硝唑相比，化合物6b具有更好的抗氧活性和更低的毒性。
• Structure-guided discovery of 1,3,5-triazine–pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate
  作者：Babita Singh、Hans Raj Bhat、Mukesh Kumar Kumawat、Udaya Pratap Singh

  DOI：10.1016/j.bmcl.2014.05.103

  日期：2014.8

  Impressed by the exceptional antibacterial activity exhibited by our earlier designed molecules originating from 1,3,5-triazine, the present study was undertaken to synthesize a novel series of 1,3,5-triazine-pyrazole conjugates to bring diversity around the core skeleton. The target analogues showed potent antibacterial activity against tested Gram-positive and Gram-negative microorganisms. The toxicity and metabolic site prediction studies were also held out to set an effective lead candidate for the future antibacterial drug discovery initiatives. (C) 2014 Elsevier Ltd. All rights reserved.